|Articles|February 19, 2016

Translational Medicine: A “Team Sport”?

Author(s)DIA

February 19, 2016

Translational Medicine: A “Team Sport”?

Dr. Makoto Suematsu, President of the Japan Agency for Medical Research & Development (AMED); and Dr. Christopher P. Austin, Director of the National Center for Advancing Translational Sciences (NCATS), US National Institutes of Health; discuss how collaboration between their agencies will ultimately deliver better therapies more quickly to more patients.

Read the article here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Translational Medicine: A “Team Sport”?

Related Content

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

How to Rebuild Pharma Operating Model for an AI Era

From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle

From Value Imperative to Operating Reality: Rethinking Trust in Pharma

Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs

Trending on PharmExec

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

When Drug Pricing Becomes Trade Policy

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

FDA Approves Pasatru For Adults With Fibrodysplasia Ossificans Progressiva